Appili Therapeutics Company Description

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada.

Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.

The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Appili Therapeutics Inc.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Dr. Donald D. Cilla Jr., M.B.A., Pharmd

Contact Details

Address: #21-1344 Summer Street Halifax, NS B3H 0A8 Canada
Phone	902-442-4655
Website	appilitherapeutics.com

Stock Details

Ticker Symbol	APLI
Exchange	Toronto Stock Exchange
Fiscal Year	April - March
Reporting Currency	CAD
ISIN Number	CA03783R1073

Key Executives

Name	Position
Dr. Donald D. Cilla Jr., M.B.A., Pharmd	Chief Executive Officer, President and Director
Kenneth G. Howling	Chief Financial Officer
Dr. Gary S. Nabors Ph.D.	Chief Development Officer